NCT00783406 - Safety, Toleration and Efficacy of Single Inhaled Doses of PF-00610355 in Chronic Obstructive Pulmonary (COPD) Patients. | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 31, 2008

Primary Completion Date

March 31, 2009

Study Completion Date

March 31, 2009

Conditions

Pulmonary Disease, Chronic Obstructive

Interventions

DRUG

PF-00610355

dry powder inhaler, 1472 mcg, single dose

DRUG

PF-00610355

dry powder inhaler, 736 mcg, single dose

DRUG

PF-00610355

dry powder inhaler, 368 mcg, single dose

DRUG

Placebo

Trial Locations (2)

Pfizer Investigational Site, Berlin

Pfizer Investigational Site, Wiesbaden